Dr. Kerkar joined EXUMA Biotech in September 2020 from Eli Lilly & Company, where he served as Associate Vice President of Immuno-oncology. Previously, he was a Distinguished Research Fellow at Boehringer-Ingelheim Pharmaceuticals, and Associate Director, Translational Medicine & Pathology, at Bristol-Myers Squibb. Dr. Kerkar completed post-doctoral research and clinical fellowships at the NCI and NIH Clinical Center. Dr. Kerkar earned his M.D. with distinction in biomedical research from the Wayne State University School of Medicine in Detroit, Michigan and a B.A. from Kalamazoo College, Kalmazoo, Michigan.